眼科 ›› 2014, Vol. 23 ›› Issue (1): 43-46.doi: 10.13281/j.cnki.issn.1004-4469.2014.01.011

• 论著 • 上一篇    下一篇

乙胺丁醇视神经病变临床特征分析

刘子豪   李红阳  姜兆财  魏世辉   

  1. 100853 北京,解放军总医院眼科
  • 收稿日期:2013-08-11 出版日期:2014-01-25 发布日期:2014-01-22
  • 通讯作者: 魏世辉,Email:weishihui706@hotmail.com

Clinical characteristics of ethambutol optic neuropathy: 17 cases report

 LIU  Zi-Hao,   Li-Hong-Yang, JIANG  Zhao-Cai, WEI  Shi-Hui   

  1. Department of Ophthalmology, General Hospital of PLA, Beijing 100853, China
  • Received:2013-08-11 Online:2014-01-25 Published:2014-01-22
  • Contact: WEI Shi-hui, Email: weishihui706@hotmail.com

摘要: 目的  分析乙胺丁醇视神经病变(ethambutol optic neuropathy,EON)患者的临床特征。 设计 回顾性病例系列。 研究对象 解放军总医院神经眼科EON患者17例。 方法  回顾EON患者病历中记录的发病情况及初诊和复诊时的临床表现、治疗结果。 主要指标 矫正视力、眼底改变、视野、色觉。 结果  乙胺丁醇平均服药时间(8.0±4.0)个月,平均用药剂量(166.8±82.9) g。所有患者均为双眼发病。28眼(82.4%)表现为慢性、进行性、无痛性视力下降,就诊时平均矫正视力(0.12±0.09),26眼(76.4%)存在视盘颜色改变,23眼(67.6%)视野表现为中心暗点,20眼(58.8%)表现红绿色盲。所有患者均未表现有视交叉及视神经核磁异常信号。口服甲钴胺治疗后平均随访(8.6±3.8)个月,矫正视力提高至(0.34±0.15)(P=0.000)。结论  EON表现为双眼发病,多为慢性进行性视力下降,主要损伤乳头黄斑束神经纤维。其视功能损害是可逆或部分可逆的。(眼科,2014,23:43-46)

关键词: 乙胺丁醇, 视神经病变

Abstract: Objective To study the clinical features of ethambutol optic neuropathy (EON). Design Retrospective case series. Participants 17 patients diagnosed as EON in PLA General Hospital. Method General condition, clinical characteristics, and treatment outcome of all 17 patients based on medical records were analyzed. Main Outcome Measures Best corrected visual acuity, visual field, color vision, color of optic disc. Results The average duration of ethambutol use is (8.0±4.0) months, and the average dosage is (166.8±82.9) g. Both eyes were affected in all patients. 28 eyes (82.4%) were characterized with chronic, progressive, painless vision loss. The mean best corrected visual acuity was (0.12±0.09) at first visit. 26 eyes (76.4%) had optic disc color change. 23 eyes (67.7%) showed central scotoma of visual field. 20 eyes (58.8%) manifested anerythrochloropsia. Abnormal signals of optic chiasma were not detected on magnetic resonance imaging in all the 17 cases. The best corrected visual acuity was raised to (0.34±0.15) in the last follow-up (average 8.6±3.8 months) after oral mecobalamine. Conclusion EON affects both eyes, manifested with chronic, progressive vision loss. It mainly implicates fasciculus macula papillaris and the visual impairment is reversible or partially reversible. (Ophthalmol CHN, 2014, 23: 43-46)

Key words: ethambutol, optic neuropathy